Company Profile
SpringWorks Therapeutics Stock Price, News & Catalysts
- Ticker:
- SWTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for SWTX.
Company overview
Business overview
SpringWorks Therapeutics is a rare-disease and oncology biotech focused on targeted treatments for genetically defined conditions. Its story blends commercial execution with a highly focused pipeline.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, SpringWorks sits in specialty biopharma.
Business Model Characteristics
The company combines product revenue with pipeline development, so investors watch launch progress, label expansion, and regulatory milestones.
Position Within the Biotechnology Landscape
SpringWorks is a focused specialty-biotech name whose stock can move sharply on data and commercial milestones.
Future catalysts
- SpringWorks's catalysts are nirogacestat in desmoid tumors and mirdametinib in NF1-PN, both of which can move the stock if commercial and late-stage execution stay clean. The company is still building its rare-disease franchise.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does SpringWorks Therapeutics do?
SpringWorks Therapeutics is a rare-disease and oncology biotech focused on targeted treatments for genetically defined conditions. Its story blends commercial execution with a highly focused pipeline.
On which exchange is SWTX stock listed?
SpringWorks Therapeutics (SWTX) is associated with NASDAQ, United States, Biopharma.
What is nirogacestat?
SpringWorks's catalysts are nirogacestat in desmoid tumors and mirdametinib in NF1-PN, both of which can move the stock if commercial and late-stage execution stay clean.
Which conditions is SpringWorks Therapeutics targeting with nirogacestat?
SpringWorks Therapeutics is associated with oncology, genetic disease based on its company overview and current catalyst commentary.
How does SpringWorks Therapeutics describe recent progress with nirogacestat?
SpringWorks's catalysts are nirogacestat in desmoid tumors and mirdametinib in NF1-PN, both of which can move the stock if commercial and late-stage execution stay clean.
What is mirdametinib?
SpringWorks's catalysts are nirogacestat in desmoid tumors and mirdametinib in NF1-PN, both of which can move the stock if commercial and late-stage execution stay clean.
What should investors watch for with mirdametinib?
SpringWorks's catalysts are nirogacestat in desmoid tumors and mirdametinib in NF1-PN, both of which can move the stock if commercial and late-stage execution stay clean.
What is SpringWorks?
SpringWorks Therapeutics is a rare-disease and oncology biotech focused on targeted treatments for genetically defined conditions.